Study to Assess the Absorption, Metabolism and Excretion of \[14C\]AZD8931 after a Single-Dose Oral Administration
Study Type
INTERVENTIONAL
Allocation
NA
Masking
NONE
Enrollment
6
Single 160 mg oral dose administered on Day 1
Research Site
London, United Kingdom
To investigate the absorption, distribution, metabolism and excretion of AZD931 in human subjects
Time frame: Multiple blood , urine and faecal samples from pre-dose until 240 hours post last dose
To investigate the pharmacokinetic variable of AZD8931 in plasma
Time frame: Multiple PK blood samples from pre-dose until 240 hours post last dose
To investigate the safety and tolerability of AZD8931 given orally
Time frame: Frequent safety measurements during the study from screening period to follow-up
To investigate the AZD8931 metabolites variables in plasma
Time frame: Multiple PK blood samples from pre-dose until 240 hours post last dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.